Abstract:Abstract Background Checkpoint inhibitors (CPIs) are used to treat solid organ metastatic malignancies. They act by triggering a vigorous immune response against tumoural cells, preventing their proliferation and metastasis. However, this is not a selective response and can cause immune-related adverse events (irAEs). The kidney can potentially be damaged, with an incidence of irAEs of 1–4%. The most frequent type of toxicity described is acute interstitial nephritis (AIN). Methods We conducted a study of patients with solid organ metastatic malignancies treated with immunotherapy who developed acute renal injury and underwent kidney biopsy in the last 14 months at the Vall d’Hebron University Hospital. Results In all, 826 solid organ malignancies were treated with immunotherapy in our centre, 125 of them (15.1%) developed acute kidney injury (AKI), 23 (18.4% of AKI) visited the nephrology department and 8 underwent kidney biopsy. The most frequent malignancy was lung cancer, in five patients (62%), followed by two patients (25%) with melanoma and one patient (12%) with pancreatic cancer. Four patients (50%) had already received previous oncological therapy, and for the remaining four patients (50%), CPI was the first-line therapy. Five patients (62%) were treated with anti-programmed cell death protein 1, three patients (37%) received anti-programmed death ligand 1 and two (25%) patients were treated in combination with anti-cytotoxic T-lymphocyte antigen 4. The time between the start of CPI and the onset of the AKI ranged from 2 to 11 months. The most frequent urine findings were subnephrotic-range proteinuria, with a mean protein:creatinine ratio of 544 mg/g (standard deviation 147) and eosinophiluria. All patients were biopsied after being diagnosed with AIN. Three patients (37%) received treatment with pulses of methylprednisolone 250–500 mg/day and five patients (62%) received prednisone 1 mg/kg/day. Seven patients (87%) experienced recovery of kidney function and one patient (12%) progressed to chronic kidney disease. Conclusions We report on eight patients with CPI-related AIN diagnosed in the last 14 months at our centre. The novel immunotherapy treatment of metastatic solid organ malignancies carries a higher risk of irAEs. The kidney is one of the most commonly affected organs, frequently presenting as an AIN and exhibiting a favourable response to steroid treatment.

Acute Interstitial Nephritis Associated with Sofosbuvir and Daclatasvir

Treatment of Chronic Hepatitis C Viral Infection with Sofosbuvir and Daclatasvir in Kidney Transplant Recipients

Recurrent membranous nephropathy and acute cellular rejection in a patient treated with direct anti-HCV therapy (ledipasvir/sofosbuvir)

Acute Tubulointerstitial Nephritis in a Patient on Anti-Programmed Death-Ligand 1 Triggered by COVID-19: A Case Report

Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use

Acute kidney injury from immune checkpoint inhibitor use

Safety and Efficacy of Sofosbuvir-Based Treatment of Acute Hepatitis C in End-Stage Renal Disease Patients Undergoing Haemodialysis

Membranous Nephropathy Associated With Hepatitis C Virus Infection Treated With Corticosteroids And Ledipasvir-Sofosbuvir: A Case Report And Review Of Literature

A case of biopsy-proven acute interstitial nephritis following atezolizumab-bevacizumab treatment of advanced unresectable hepatocellular carcinoma

Rapidly progressive glomerulopathy in a patient with hepatitis C virus not diagnosed. Case Report.

Sofosbuvir and ledipasvir decreased nephrotic syndrome caused by IgA nephropathy with a membranoproliferative pattern of injury in hepatitis C virus-induced cirrhosis: a case report

Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency

Acute interstitial nephritis related to immune checkpoint inhibitors

COMBINED NS5A & NS5B NUCLEOTIDE INHIBITOR THERAPY FOR PATIENTS WITH CHRONIC HEPATITIS C WITH STAGE 5 CHRONIC KIDNEY DISEASE ON HEMODIALYSIS

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients

Facial and bilateral lower extremity edema due to drug-drug interactions in a patient with hepatitis C virus infection and benign prostate hypertrophy: A case report

Recurrent Hyperkalemia in Patients with Chronic Kidney Disease and Hepatitis C Treated with Direct Antiviral Agents

Nivolumab-associated acute glomerulonephritis: a case report and literature review

Acute-on-chronic liver failure induced by antiviral therapy for chronic hepatitis C: A case report

Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience

Changes in renal function in patients with chronic hepatitis C treated with sofosbuvir‐velpatasvir